SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board:
Last Post: 9/28/2016 6:51:00 PM - Followers: 167 - Board type: Free - Posts Today: 11

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CVM News: Current Report Filing (8-k) 05:23 PM
CVM News: CEL-SCI Reports Clinical Hold on Head and Neck Cancer Study 09/26/2016 11:03:00 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 09/23/2016 05:12:00 PM
CVM News: CEL-SCI Announces Resignation of its Founder for Health Reasons 09/06/2016 08:30:00 AM
CVM News: CEL-SCI Reports Monthly Patient Enrollment in August for Its Phase 3 Head and Neck Cancer Trial 09/02/2016 09:00:00 AM
News News Alert: Current Report Filing (8-k) 09/28/2016 05:23:00 PM
PostSubject
#8718  Sticky Note Do with this information what you will,... I drkazmd65 09/26/16 01:49:06 PM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#8796   8k released with little to no information. trickledownfacists 09/28/16 06:51:00 PM
#8795   Any guess as to number of enrollees this Turney 09/28/16 05:54:23 PM
#8794   Not as yet. drkazmd65 09/28/16 04:00:57 PM
#8793   I bought a bit more at 0.267... Foxwoods Man 09/28/16 03:54:20 PM
#8792   I am back in to chance it for ducruacuteo11 09/28/16 03:23:10 PM
#8791   Anyone here back from the company? trickledownfacists 09/28/16 02:25:38 PM
#8790   Added at this price steve2150 09/28/16 11:28:15 AM
#8789   Their verbal response was" we don't know why trickledownfacists 09/28/16 11:27:56 AM
#8788   Cel-Sci should absolutely know the reason for the mikedel 09/28/16 11:26:04 AM
#8787   I think I get your point here learning drkazmd65 09/28/16 10:39:10 AM
#8786   Cvm is a pony. Most , if not learning curve 09/28/16 02:05:55 AM
#8785   Look. This could be the exacta. jamdoc 09/27/16 10:15:59 PM
#8784   It took JUNO therapeutics one week to clear trickledownfacists 09/27/16 09:38:48 PM
#8783   Well Well. This is a big surprise. jamdoc 09/27/16 09:19:50 PM
#8782   Nice job! Thank you PinkZombie 09/27/16 08:14:49 PM
#8781   * * $CVM Video Chart 09-27-16 * * ClayTrader 09/27/16 05:13:55 PM
#8780   Looks like oct. we will know how the trickledownfacists 09/27/16 02:32:37 PM
#8779   Same here as well morecheese 09/27/16 01:05:04 PM
#8778   Same trickledownfacists 09/27/16 12:47:17 PM
#8777   Just might regret this in a few days,... drkazmd65 09/27/16 12:39:48 PM
#8776   Could just be a coincidence tdf - but drkazmd65 09/27/16 12:02:42 PM
#8775   Thoughts on the hold and the start of trickledownfacists 09/27/16 11:45:49 AM
#8774   I always picked the right time to buy ducruacuteo11 09/27/16 11:43:13 AM
#8773   http://www.fiercebiotech.com/biotech/cara-shares-surge-after-fda-lifts-a-hold-on trickledownfacists 09/27/16 11:38:47 AM
#8772   http://www.xconomy.com/boston/2014/03/31/fda-lifts-clinical-hold-on-curis-cancer trickledownfacists 09/27/16 11:33:41 AM
#8771   http://seekingalpha.com/news/3165967-fda-lifts-partial-clinical-hold-medivations trickledownfacists 09/27/16 11:33:19 AM
#8770   https://www.google.com/amp/www.cnbc.com/amp/2016/07/12/juno-therapeutics-shares- trickledownfacists 09/27/16 11:30:27 AM
#8769   CVM A problem with the "cold fill facility? dpm58 09/27/16 11:08:27 AM
#8768   Low teens. willlbone 09/27/16 10:19:58 AM
#8767   I have not asked anything yet - was drkazmd65 09/27/16 09:41:32 AM
#8766   Any word from Gavin? trickledownfacists 09/27/16 09:28:43 AM
#8765   The reason is probably (ii) since safty is mikedel 09/27/16 09:23:46 AM
#8764   The reason is probably (ii) since safty is mikedel 09/27/16 09:23:27 AM
#8763   I was wondering what the post market hold Investor_cmz 09/27/16 08:24:54 AM
#8762   I hope the company makes an announcement before Foxwoods Man 09/27/16 08:22:17 AM
#8761   Look's like low 20's rather than low 30's Foxwoods Man 09/27/16 08:03:37 AM
#8760   Wouldn't you think that if a company is Foxwoods Man 09/27/16 07:46:31 AM
#8759   IMO - you are essentially correct here JakeJ. drkazmd65 09/27/16 07:33:39 AM
#8758   The clinical hold order may be made by trickledownfacists 09/27/16 02:31:38 AM
#8757   Hey! Poker players....playing against each other rather than learning curve 09/27/16 02:31:22 AM
#8756   If I see any retrial buying of significance learning curve 09/27/16 02:20:49 AM
#8755   Why need explanation? learning curve 09/27/16 02:18:01 AM
#8754   FYI: somebody moving 60k shares in search of learning curve 09/27/16 02:11:51 AM
#8753   Me, you, Donald, and Hillary at a bar..... learning curve 09/27/16 01:59:40 AM
#8752   The change from 10% to 6.5% needs explanation, JakeJ 09/27/16 01:51:49 AM
#8751   Vote Donald and you'll have your answer faster learning curve 09/27/16 01:38:59 AM
#8750   Don't know the answers to your questions, but ombay1 09/27/16 01:21:20 AM
#8749   Does the FDA put a hold on a trickledownfacists 09/27/16 12:43:27 AM
#8748   Just speculation on my part, but maybe has ombay1 09/27/16 12:33:48 AM
#8747   So why would they let them continue to trickledownfacists 09/27/16 12:25:45 AM
PostSubject